Acrivon Therapeutics, Common Stock Analysis

Acrivon Stock Analysis Notes

About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.09. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acrivon Therapeutics, recorded a loss per share of 2.72. The entity had not issued any dividends in recent years. For more info on Acrivon Therapeutics, Common please contact the company at 617 207 8979 or go to https://www.acrivon.com.

Acrivon Therapeutics, Investment Alerts

Acrivon Therapeutics, Upcoming and Recent Events

Acrivon Largest EPS Surprises

View All Earnings Estimates

Acrivon Therapeutics, Environmental, Social, and Governance (ESG) Scores

Acrivon Stock Institutional Investors

Note, although Acrivon Therapeutics,'s institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acrivon Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 235.39 M.

Acrivon Profitablity

Management Efficiency

Acrivon Therapeutics, has return on total asset (ROA) of (0.2441) % which means that it has lost $0.2441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3778) %, meaning that it created substantial loss on money invested by shareholders. Acrivon Therapeutics,'s management efficiency ratios could be used to measure how well Acrivon Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. Net Tangible Assets is likely to climb to about 205.8 M in 2024, whereas Total Assets are likely to drop slightly above 117.8 M in 2024.

Technical Drivers

As of the 17th of October 2024, Acrivon Therapeutics, shows the Downside Deviation of 3.86, mean deviation of 3.38, and Risk Adjusted Performance of 0.0188. Acrivon Therapeutics, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acrivon Therapeutics, standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Acrivon Therapeutics, is priced correctly, providing market reflects its regular price of 7.87 per share. Given that Acrivon Therapeutics, has jensen alpha of (0.05), we suggest you to validate Acrivon Therapeutics, Common's prevailing market performance to make sure the company can sustain itself at a future point.

Acrivon Therapeutics, Price Movement Analysis

Acrivon Therapeutics, Insider Trading Activities

Acrivon Therapeutics, Outstanding Bonds

Acrivon Therapeutics, Predictive Daily Indicators

Acrivon Therapeutics, Corporate Filings

Acrivon Therapeutics, Forecast Models

Acrivon Therapeutics,'s time-series forecasting models are one of many Acrivon Therapeutics,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acrivon Therapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Acrivon Therapeutics, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acrivon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Acrivon Therapeutics,. By using and applying Acrivon Stock analysis, traders can create a robust methodology for identifying Acrivon entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acrivon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acrivon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Acrivon Therapeutics, Common stock analysis indicators help investors evaluate how Acrivon Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acrivon Therapeutics, shares will generate the highest return on investment. By understating and applying Acrivon Therapeutics, stock analysis, traders can identify Acrivon Therapeutics, position entry and exit signals to maximize returns.

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.